PRELUDE CAPITAL MANAGEMENT, LLC - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 107 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2023. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q1 2023$25,032
+92.6%
16,688
+45.6%
0.00%
Q3 2022$13,000
-68.3%
11,465
-34.6%
0.00%
-100.0%
Q1 2021$41,00017,5290.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2023
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders